Healthcare
Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update
Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical outcome measuresHigh patient and investigator enthusiasm continues with additional participants in the OL study dosed in July and several adults and adolescents in screening as of month-end Rolling BLA submission seeking accelerated approval underway, with the first module submitted and completion
About this update from Larimar Therapeutics, Inc.
BALA CYNWYD, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its second quarter 2026 operating and financial results. "This is a defining period for Larimar as we advance nomlabofusp toward potential approval, supported by a clear path to submission, a robust data package, and continued clinical momentum," said Carole Ben-Maimon, MD, President and Chief Executive Officer of Larimar. "Open label (OL) study data announced in June further reinforce the disease-modifying potential of nomlabofusp, demonstrating continued directional improvements in key clinical endpoints over time alongside a well-characterized safety profile. Following receipt of minutes from a successful Type B multidisciplinary pre-BLA meeting with the Food and Drug Administration (FDA), the first module of our rolling Biologics License Application (BLA) has been submitted, with completion expected in the second half of 2026. We continue to see strong enthusiasm from patients and investigators as we advance the OL study with additional participants dosed in July and several adults and adolescents in screening. We are also on track to initiate dosing in our global confirmatory study this quarter. Looking ahead, we are focused on execution as we work to bring forward nomlabofusp as the first potential therapy to address the underlying cause of disease for pediatric and adult patients living with Friedreich's ataxia (FA)." Highlights 1Modified Friedreich Ataxia Rating Scale (mFARS), FARS-Activities of Daily Living (FARS-ADL), 9-hole peg test (9-HPT) Upcoming Milestones Second Quarter 2026 Financial Results As of June 30, 2026, the Company had cash, cash equivalents and marketable securities totaling $156.3 million. The Company projects its cash runway into the third quarter of 2027. Second quarter of 2026 compared to the second quarter of 2025 The Company reported a net loss for the second quarter of 2026 of $32.8 million, or $0.30 per common share, compared to a net loss of $26.2 million, or $0.41 per common share, for the second quarter of 2025. Research and development expenses for the second quarter of 2026 were $28.0 million compared to $23.4 million for the second quarter of 2025. The increase in research and development expen...
View stock analysis, news, and events for Larimar Therapeutics, Inc.